| Date | Title | Description |
| 10.09.2026 | Pharma Companies Turn to Strategic CDMO Partnerships as Development Needs Evolve | SAN DIEGO, CA, UNITED STATES, September 10, 2026 /EINPresswire.com/ -- Pharmaceutical companies are rethinking how they choose development and manufacturing partners. As pipelines expand into peptides, oligonucleotides, targeted protein deg... |
| 27.08.2026 | Boston Scientific Cyberattack Halts Shipments: Weeks of Device Delays Threaten Hospital Supply | By Brandon Fisher
Published: Aug 27 2026, 1:41 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 11.08.2026 | BioNTech Alumni Launch AI Cancer Surveillance for 40M: No Clinical Proof Yet | By Alfredo Hanson
Published: Aug 11 2026, 11:50 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 06.08.2026 | mFLUSIVA Approved: FDA Clears mRNA Flu Shot, Unlocking Combo and Pandemic Vaccine Resubmission | By Clayton Lewis
Published: Aug 06 2026, 8:17 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 31.07.2026 | Moderna Norovirus Vaccine Fails Interim Bar: Trial Extends Into Fourth Season | By Collin Mercer
Published: Jul 31 2026, 9:16 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 31.07.2026 | In Vivo CAR-T’s Liver Problem Now Has Targeted Answer: CREATE Acquires Monash’s 8-Fold LNP Fix | By Benjamin Eddie
Published: Jul 31 2026, 1:14 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 31.07.2026 | The Quiet Money Behind Big Questions: Foundations Funding AI Safety, Consciousness and the Science of Mind | For most of the modern philanthropic era, the big money has flowed toward the measurable: vaccines delivered, schools built, acres conserved. Over the past decade, a distinct class of funders has emerged with a different premise. They belie... |
| 21.07.2026 | Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first | San Diego-based Axiom Biosciences plans to seek a primary listing in Hong Kong in 2027, followed by a secondary U.S. listing in 2029.
Global biotech firms are increasingly eyeing Hong Kong for its growing investor base and its proximity to ... |
| 08.07.2026 | The Role of CROs and CDMOs in Supporting Global Drug Development | SAN DIEGO, CA, UNITED STATES, July 8, 2026 /EINPresswire.com/ -- A CRO/CDMO that can support global drug development should combine modality-specific technical expertise, global regulatory experience, scalable manufacturing, mature quality ... |
| 24.06.2026 | Genetic Heart Disease Has No Approved Cure: Merck KGaA Bets $50M on Gene Modulation Startup | By Chase Fiorini
Published: Jun 24 2026, 11:08 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 17.06.2026 | Surgical Robotics AI Gets a Commercial Foundation: Nvidia GR00T-H-N1.7 Arrives | By Richard L. Wells
Published: Jun 17 2026, 14:42 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 08.06.2026 | KRAS Cancer Treatment: J&J Acquires Firefly Bio for $1B to Destroy, Not Block, Tumor Protein | By Chase Fiorini
Published: Jun 08 2026, 15:49 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 04.06.2026 | GPT-Rosalind Drug Discovery Update: OpenAI Cuts Genomics Compute, Expands Global Access | By Shannon Harwood
Published: Jun 04 2026, 06:55 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 19.05.2026 | FDA blocked melanoma drug as confusion reigned under Makary | Getting your Trinity Audio player ready...
By Arthur Allen, KFF Health News
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw that the drug ha... |
| 15.05.2026 | Стартап из США приобрел у Novo Nordisk права на терапию болезни Паркинсона | Стартап из США приобрел у Novo Nordisk права на терапию болезни Паркинсона
Бостонская компания Cellular Intelligence приобрела разрабатываемую датской Novo Nordisk клеточную терапию болезни Паркинсона STEM-PD, сообщается на ее сайте.
Выйти ... |
| 15.05.2026 | Стартап из США приобрел у Novo Nordisk права на терапию болезни Паркинсона | Стартап из США приобрел у Novo Nordisk права на терапию болезни Паркинсона
Бостонская компания Cellular Intelligence приобрела разрабатываемую датской Novo Nordisk клеточную терапию болезни Паркинсона STEM-PD, сообщается на ее сайте.
Novo N... |
| 31.12.2025 | A family is trying to raise millions to test gene therapy that could help kids trapped in bodies they can’t move | Getting your Trinity Audio player ready...
At first, Everly Green’s parents didn’t understand why her doctors wanted genetic testing. Their daughter was behind on her milestones at 18 months, but was gradually making progress, and they expe... |
| 04.09.2025 | The Strategic Blueprint of Vivek Acharya: Navigating AI's Future in Healthcare | Created by Carl Williams
Published: Sep 04 2025, 00:21 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 02.09.2025 | Five ARCH-backed companies and executives named to Fierce 50 list of those making a significant impact in the biopharma and healthcare industries | - |
| 25.08.2025 | Kennedy’s anti-vaccine strategy risks forcing shots off market, manufacturers warn | Kennedy has said changes to the U.S. vaccine system are needed because, he asserts without evidence, immunizations are linked to autism, neurotoxicity, allergies, and death. He is a leader of the “Make America Healthy Again” movement, an in... |
| 21.07.2025 | FDA taps biotech industry veteran as RFK Jr.’s top drug regulator | The Food and Drug Administration said it has appointed former biotech executive George Tidmarsh as the agency’s top drug regulator.
Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University’s School of Medicine, wi... |
| 19.06.2025 | The Dawn of Targeted Cancer Therapies: A New Era Beyond Chemotherapy | Cancer treatment is on the brink of a revolution. The days of chemotherapy, with its harsh side effects and systemic impact, may soon be numbered. Enter antibody-drug conjugates (ADCs), a class of targeted therapies that promise to deliver ... |
| 18.06.2025 | Fierce Biotech Fundraising Tracker '25: Actio raises $66M series B; Draig draws in $140M | A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry.
We're maintaining the criteria we used for last year's tracker, which means including financing... |
| 17.06.2025 | Targeted cancer drugs may replace chemo for some patients — and drugmakers say they’re getting closer | The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects.
There is still more work to be done to refine antibody-drug conjugates, but some are ... |
| 16.06.2025 | Eliminating Cancer Treatment Side-Effects Through Targeted Drug Delivery | Tim Barrow-Williams, Head of Drug Delivery at PA Consulting Bill Hartman, Pharma and Medtech Design Expert at PA Consulting
Last year, the American Cancer Society predicted that in 2024, the US would reach two million annual new cancer case... |
| 05.06.2025 | It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech | Out of five critical tech sectors, “China has the most immediate opportunity to overtake the United States in biotechnology,” the Harvard Belfer Center said in a new report.
Just as China is developing its biotech sector, reports from the U... |
| 15.05.2025 | AI-powered drug development startup Pathos AI closes $365M investment
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mission to provide fre... | Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding.
The company didn’t disclose the investors in the Series D round. According to Fi... |
| 31.12.2024 | How Digital Twins Open The Door for Next-Gen Clinical Trials | Arijit Chatterjee, Pharma & Med Tech Solutions Engineering Leader, Capgemini Americas
Clinical trials have been the cornerstone of medical innovation for centuries, but as the effort continues to improve patient care and speed the devel... |
| 27.07.2024 | MRNS Deadline: MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit | NEW YORK, July 27, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceutica... |
| 27.06.2024 | MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit | NEW YORK, June 27, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceutica... |
| 20.06.2024 | MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit | NEW YORK, June 20, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceutica... |
| 19.06.2024 | ElevateBio: компания по производству генетических лекарств | Содержание
История компании
Технологии: объединение производства и некстген технологий терапевтического производства
Экосистема компании
BaseCamp
Партнеры
Отраслевые партнерства
Академические партнерства
Привлечение инвестиций История компа... |
| 13.06.2024 | MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit | NEW YORK, June 13, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all persons and entities that purchased securities of Marinus Pharmaceutica... |
| 03.06.2024 | Health | Psychoactive drugs are having a moment. The FDA will soon weigh in | Proponents hope the efforts could yield the first major new therapies for mental illness since the introduction of modern antidepressants in the 1980s. But not all researchers are convinced that their benefits have been validated, or proper... |
| 21.05.2024 | R3 Vascular's Breakthrough in the Medical Device Landscape | R3 Vascular, a pioneering medical device company based in Mountain View, California, has recently captured the attention of the industry with its groundbreaking bioresorbable scaffold for peripheral artery disease. Securing an impressive $8... |
| 20.05.2024 | R3 Vascular raises $87M for peripheral artery disease stent | figcaption>span]:font-sans">
R3 Vascular raised an $87 million Series B for its bioresorbable scaffold for peripheral artery disease.
Why it matters: While still in trial phase, R3 emerges as a potential competitor to Abbott, the... |
| 11.04.2024 | Digital Health Apps Graveyard: Why 53% Fail and How to Succeed | Shameem C Hameed, Founder and CEO of blueBriX
The digital market is flooded with health apps. Over 90,000 offers were introduced to patients and healthcare providers alike in 2020 alone, with this number continuing to rise in response to mo... |
| 29.03.2024 | A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug | Health A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
Hilary Brueck
2024-03-29T16:38:44Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email... |
| 25.03.2024 | Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome | TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating
Prader Willi syndrome is the most common genetic cause of life-threatening childhood obesity
... |
| 09.02.2024 | Does Moderna’s RSV vaccine lose efficacy faster than others? | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Our podcast this week centers exclusively on a tantalizing subject: Artificial intelligence in biotech. Give it a li... |
| 05.02.2024 | Regeneron is interested in obesity treatments that combat muscle loss | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk about two players that want to join the obesity market with updates to the GLP-1 class: Amgen and Reg... |
| 29.01.2024 | These are the 7 healthcare startups primed to IPO when the market reopens | Premium Tech These are the 7 healthcare startups primed to IPO when the market reopens
Rebecca Torrence
2024-01-29T10:00:01Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email icon An envelope. It in... |
| 26.01.2024 | Eli Lilly overtakes Tesla in market value | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a look at a biotech rarity, a milestone on Wall Street, and pharma’s latest run-in... |
| 24.01.2024 | Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. So, today we talk about how Eli Lilly’s gene therapy, developed by Akuous, worked in a child born with an... |
| 22.01.2024 | Investigators fault Lilly plant for manufacturing issues | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, lots of regulatory content! We talk about march-in rights and chastening TikTok influencers for their prescri... |
| 08.01.2024 | Biopharma M&A ripens as JPM launches | The JPMorgan Health Care Conference — the definitive launchpad for industry dealmaking — kicked off Monday.
Why it matters: As interest rates stabilize and the funding market for biotech rebounds, there will be plenty of white space in phar... |
| 08.01.2024 | Alphabet’s AI-driven drug discovery startup Isomorphic lands $3 billion pharma deals with Lilly and Novartis | Alphabet’s Isomorphic, an AI-driven drug discovery startup, has scored two major deals from pharmaceutical giants Eli Lilly and Novartis, ringing in at nearly $3 billion combined. These deals will notably bolster Google DeepMind’s AlphaFold... |
| 05.01.2024 | Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy? | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we discuss why a cell therapy stalwart is pivoting, and why a Feng Zhang startup is laying off a quart... |
| 02.01.2024 | Today’s at-home microbiome testing industry is fraught with snake oil | The blue muffin challenge. Food sensitivity tests. Microbiome test kits.
Self-help gastrointestinal health is all the rage. Rightly so: One in four Americans is affected by digestive disorders. And we’re all eating worse, sleeping less, and... |
| 30.12.2023 | CRISPR в генотерапии. История и право | Рис.1| Здесь изображена эндонуклеаза Cas9 за работой.Введение
CRISPR – это революционная технология генной инженерии, которая позволяет точно редактировать ДНК. Применение его в генотерапии может изменить жизнь миллионов людей с генетически... |
| 28.12.2023 | Lost In The Latest Apple Watch Patent Battle: The ITC Loophole Creates A Mess | If you follow tech news at all, you likely heard some stuff about the potential for an Apple Watch ban over patent infringement. It was all over the news. Apple had pulled its high end watches from its store last week, following an ITC ruli... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry.
While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 20.12.2023 | Inhaled vaccines could stop Covid infections, monkey studies show | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. Today, we get into why Amy Abernethy is leaving Verily, and why the ongoing reckoning with AI doesn’t nec... |
| 18.12.2023 | Point Bio Prostate Cancer Therapy Meets Phase 3 Goal, But Results Still Disappoint | A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well the drug will match up against a rad... |
| 11.12.2023 | VCs are getting pickier about their weight-loss bets as startups rush to prescribe Ozempic | Healthcare VCs are getting pickier about their weight-loss bets as startups rush to prescribe Ozempic
Rebecca Torrence
2023-12-11T10:26:01Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email icon An ... |
| 06.12.2023 | These 3 men claim they've reversed their biological age. Here are their daily routines. | Health These 3 men claim they've reversed their biological age. Here are their daily routines.
Amber Middleton and Hilary Brueck
Updated
2023-12-06T17:33:21Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Faceb... |
| 05.12.2023 | The 20 young leaders who are building a new future for the real-estate industry in 2023 | Natasha Sadikin, Ankur Jain, Kristen Henry, Bryce Grandison James Leng, Mike Coppola, Cameron Moore, Jelissa Holder This story is available exclusively to Business Insider subscribers. Become an Insider and start reading now.
Meet Business ... |
| 01.12.2023 | Johnson & Johnson bets heavy on AI-driven drug discovery | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about h... |
| 28.11.2023 | Today’s biotech news roundup, in under 800 words | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk lots about clinical trial inconsistencies: How Canada’s trial reporting is not up to snuff, and how c... |
| 22.11.2023 | Pharmalittle: European patent agency invalidates a Moderna mRNA patent; pharma ally Eshoo plans to retire | Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalot campus. There won’t be a newsletter this Thursday or Friday because of the Thanksgiving holi... |
| 10.11.2023 | The first vaccine for the increasingly prevalent chikungunya virus is here | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we have two FDA approvals, preview late-breakers at this weekend’s American Heart Association scientific sessi... |
| 30.10.2023 | SparingVision named a ‘Fierce 15’ Company by Fierce Biotech | SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, announces that it has been named by Fierce Biotech as one of 2023’s ‘Fierce 15’ biotechnology companies, designating it as one... |
| 15.09.2023 | The Iceman Runneth | This story is available exclusively to Business Insider subscribers. Become an Insider and start reading now. Have an account? Log in.
Redeem now
Vivek Ramaswamy got rich in finance and pharma before declaring war on "wokeness." ... |
| 01.09.2023 | AstraZeneca bets that gene therapy’s workhorse will still deliver the goods | Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile... |
| 30.08.2023 | Wearable Technology and AI’s Healthcare Advancements Are Leading to Healthier Lifestyles | David Thompson, Tech Times 30 August 2023, 11:08 am
(Photo : Wearable Technology and AI’s Healthcare Advancements Are Leading to Healthier Lifestyles)
From smartwatches to heart monitors and continuous glucose monitors, the advent of artifi... |
| 14.08.2023 | Clinical data is a goldmine — but Europe's startups are struggling to grow | Malte Mueller/ Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Big Pharma and biotech companies often outsource clinical trials to external companies. Startups off... |
| 14.08.2023 | Seattle company founded by Nobel Prize winner plans human tests for experimental COVID-19 drug | Cocrystal Pharma co-founder Roger Kornberg won the Nobel Prize in Chemistry for revealing the high-resolution structure of a protein complex called RNA Polymerase II, shown here. The complex controls the synthesis of RNA (in red) from a DNA... |
| 10.08.2023 | Ozempic maker bolsters weight loss portfolio with $1 billion deal | Danish drugmaker Novo Nordisk has agreed to buy Inversago Pharma, a Montreal-based developer of anti-obesity drugs, for upwards of $1.1 billion in cash.
Why it matters: Novo isn't content to rest on its weight loss laurels, despite the popu... |
| 01.08.2023 | Startups shutting down in 2023: Tech startups that closed up shops in Q2 as venture market cools | It is undeniable that 2023 has been a challenging year for tech startups across the globe. The initial optimism that started at the beginning of this year quickly gave way to a daunting combination of banking defaults and Federal Reserve in... |
| 01.08.2023 | Verily hires former Apple Health leader Andrew Trister as chief scientific officer | As Verily aims to get on track, the Alphabet life science company has hired Andrew Trister, an oncologist and veteran of big technology companies and research, as its new chief scientific officer.
Trister will lead Verily’s population healt... |
| 27.07.2023 | Medical Devices Are Evolving Toward Specialized Solutions | Medical devices have existed in some form for centuries, resulting in thousands of innovative implementations over the years. Throughout history, medical devices have addressed a wide array of disease states – often, one device has purpose ... |
| 20.07.2023 | A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and challenges ahead | Seth Berkley, the soon-to-be former CEO of Gavi, the Vaccine Alliance, apologized for being a few minutes late jumping on a Zoom call.
Berkley — one of the highest-profile proponents of vaccination on the planet — was under a denial-of-serv... |
| 19.07.2023 | These are the 16 most promising healthcare startups of 2023, according to top VCs | Octave CEO Sandeep Acharya and Golee Abrishami, the head of clinical care. Octave This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
We asked top VCs to name the most promising healthtech st... |
| 19.07.2023 | Under the Weather? Your Smartwatch Saw It Coming | “Early detection saves lives” is a popular phrase that signifies how important monitoring, scans, and proactive measures are in detecting and treating diseases. Across the board, any illness or chronic condition benefits from early detectio... |
| 10.07.2023 | Retailers seek to shake up clinical trials business | Big retailers expanding into health care delivery increasingly see a growth opportunity tapping their huge customer bases to recruit participants into clinical trials.
Why it matters: The moves by Kroger, Walgreens and Walmart, among others... |
| 10.07.2023 | Breakthrough Alzheimer’s drug approval seen to renew dementia drug investments and increase the potential for digital dementia therapies – good news for Brain+ | Breakthrough Alzheimer’s drug approval seen to renew dementia drug investments and increase the potential for digital dementia therapies – good news for Brain+
Mon, Jul 10, 2023 08:50 CET Report this content
Copenhagen, Denmark, July 10, 20... |
| 21.06.2023 | Sanofi Goes All-In On AI | Chief Executive Officer of French pharmaceutical giant Sanofi, Paul Hudson, Paris, September 8, ... [+] 2021. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)AFP via Getty Images |
| 30.05.2023 | Inex acquires Taiwanese arm of genomics company in $4m deal | AcquisitionsNewsStartups
Shadine Taufik · 13 Jun 2023 · 1 min readInex acquires Taiwanese arm of genomics company in $4m deal
Photo credit: Zolnierek / Shutterstock
Inex Innovate, a Singapore-based molecular diagnostics firm, has acquired Y... |
| 19.05.2023 | GeekWire Awards 2023 revealed: Community honors top innovation in Pacific Northwest tech | Jake Stallman, VP of build quality and design at Carbon Robotics, snags a selfie with R2-D2 while accepting the Hardware/Gadget/Robotics of the Year Award at the 2023 GeekWire Awards. (GeekWire Photo / Kevin Lisota)
A Star Wars theme comple... |
| 18.05.2023 | An Insider View Of MedTech Software Development Trends For 2023 | Andrei Kasyanau, cofounder and CEO at Glorium Technologies. Startup advisor and an expert in health and real estate tech. |
| 17.05.2023 | Understanding the Latest Advances in Alzheimer’s Diagnostics | Alzheimer’s Diagnostics: Advancing the State of the Art
Understanding the Latest Advances in Alzheimer’s Diagnostics
This iSelect Deep Dive offers valuable insights into cutting-edge research on Alzheimer’s diagnostics. The discussion cover... |
| 17.05.2023 | A new startup looks to turn the workhorse of gene therapy against cancer | In 1980, Life and Time magazines introduced America to a new cancer wonder drug: interferon, a protein ripped from the body’s own immune system that showed exciting early results, before ultimately proving both too impotent and too toxic to... |
| 28.04.2023 | Hearing health startup TympaHealth scores $23M | Photo courtesy of TympaHealth / Business Wire |
| 21.04.2023 | This Week in European Tech: Getir and N26 face shrinking valuations, Sega buys Angry Birds maker Rovio for €706 million, fresh crypto rules in the EU, and more
24 May in Brussels Expo
What happened ... | This week, our research team tracked more than 110 tech funding deals worth over €1.1 billion, and over 20 exits, M&A transactions, rumours, and related news stories across Europe
As always, we are putting all weekly deals together for ... |
| 18.04.2023 | Protein design to precision health: Vote for Health Innovation of the Year at the GeekWire Awards | Finalists for the 2023 GeekWire Health Innovation of the Year.
This year’s nominees for the Health Innovation of the Year at the GeekWire Awards showcase a wide range of innovations from companies focused on diagnostics, therapeutics, digit... |
| 04.04.2023 | Why Sofinnova is Betting on the Confluence of Digital Technology and the Life Sciences | With the advent and adoption of digital technologies, lines have long blurred among the world of devices, pharma and purely software-driven products. And now, one European venture capital firm has decided to bet on the future of this conver... |
| 09.03.2023 | Use warranties, not outcomes-based agreements, to make payers whole when a gene therapy fails | A decade ago, I had pegged gene and cell therapies as the next frontier. As an investment banker, I was sure they would someday change how patients were treated. But a question from a biotech CEO started me thinking about not only how to pa... |
| 28.02.2023 | FDA's Billy Dunn Resigns from Post Amidst Drug Scandal on Alzheimer's—What Happened? | Isaiah Richard, Tech Times 28 February 2023, 08:02 pm
The Food and Drug Administration is in deep waters regarding the Alzheimer's drug scandal which it was facing for so long, after controversial approvals in the past, which now led to Bil... |
| 23.02.2023 | ‘A slippery slope’: A looming nationwide abortion pill ban could undermine the entire drug approval system | Soon after the Supreme Court overturned Roe v. Wade, a former Republican congressman made what might sound like an unusual offer. Did abortion pill makers want him to try to get federal legislation passed to explicitly stop states from rest... |
| 14.02.2023 | A biotech company that once claimed to have a 'cure' for COVID-19 just filed for bankruptcy, sending shares plunging 61% | Sorrento Therapeutics plunged as much as 61% on Monday after the biotech company filed for bankruptcy.
The company made headlines in 2020 after its founder claimed Sorrento discovered a COVID-19 "cure."
Advertisement
Sorrento Ther... |
| 02.02.2023 | Karuna Picks Up Kidney Drugs for Chance to Challenge Boehringer Ingelheim in the Brain | Neurological drugs developer Karuna Therapeutics is building up its pipeline with a pair of molecules initially developed for kidney disorders. It’s a small bet that could pay off in a big way by diversifying its pipeline with medicines tha... |
| 01.02.2023 | Building Bridges Between Data Silos: Mayo Clinic Platform’s Ambitious Endeavor To Enable A Learning Healthcare System | Platforms have long been disrupting industries, including healthcare, and are in an unmatched position to solve complex problems endemic to healthcare. For Dr. John Halamka, president of the Mayo Clinic Platform, the drive for platform disr... |
| 30.01.2023 | Newsletter January 2023 – Kicking off the New Year | Newsletter January 2023 – Kicking off the New Year
Mon, Jan 30, 2023 13:18 CET Report this content
The Cline team is excited to bring you the first newsletter of 2023 and look to the year ahead. In this newsletter, we will share some hi... |
| 11.01.2023 | Novartis' CEO said gene therapy is a 'nuanced puzzle' everyone is trying to figure out, but he's still committed to the cutting-edge treatments | Vas Narasimhan, the CEO of Novartis. Reuters This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Novartis' gene-therapy efforts haven't moved as fast as expected, CEO Vas Narasimhan said.
Whi... |
| 10.01.2023 | Is the golden age of biotech stocks over? | Much of the last decade felt like the golden age of biotechnology investing. Money — lots of money — was poured into new gene therapies that replaced defective genes with healthy ones, immunotherapies that were game changers for people with... |
| 30.12.2022 | This investor predicts a wave of biotech bankruptcies — and thinks it could be a 'canary in the coal mine' for other industries | Christian Angermayer, founder of Apeiron Investment Group. Apeiron Investment Group
Top biotech investor Christian Angermayer expects a wave of biotech bankruptcies in 2023.
It could be a signal to other industries that the economy won't be... |
| 22.12.2022 | Top AI startup news of the week: Jasper, Tome, Imagen AI and more | Check out all the on-demand sessions from the Intelligent Security Summit here.
From generative AI applications to healthcare and biotech, these are five AI startups — including three based in Israel — that made headlines over the past week... |
| 21.12.2022 | AI In Big Pharma: The First Antibody Designed Using AI In The Clinic | Terry Baker (right) and Jiye Shi were appointed UCB Fellows for their contributions to the design of ... [+] Bimekizumab Dr. Jiye Shi |
| 19.12.2022 | A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200% | Madrigal Pharmaceuticals is hoping to succeed where others have failed in treating NASH, a serious liver disease. Pramote Polyamate/Getty Images
Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NAS... |
| 15.12.2022 | Gates, Bezos back $75M round for Synchron’s drill-free brain-computer interface implant | After announcing that it had implanted its brain-computer interface in its first U.S. paralysis patient earlier this year, Synchron has raised $75 million to take its mind-reading tech to the next level.
The company’s series C financing,... |
